Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > COMMENTARY
COMMENTARY
- Cell Therapy Makers Working to Stand Out from Rivals by Reducing Burdens on Hospitals
April 16, 2019
- Building Credible, Convincing System Holds Key for Japan’s Cost-Effectiveness Assessment
April 2, 2019
- Generic Makers Shifting to Focus on “Specialty Area” Faced with Tougher Business Environment
March 4, 2019
- Restructuring, Divestment Progress in Wake of Drug Pricing Overhaul
February 20, 2019
- 2019 Likely to Herald Burst of “Regenerative Medicine” Approvals
January 11, 2019
- LDP Draws Up Tax Reform Outline, Revamps Credits for R&D Expenses
December 17, 2018
- After Thumbs-Up Given to Shire Buy, Weber’s Leadership Will Now Be Put to Test
December 12, 2018
- Does Dissolution of Japan Vaccine Signal Demise of Model in Vaccine Industry Vision, or Will a Second Round of JV Take Place?
November 27, 2018
- There’s Room for Growth in Biosimilar Space, but Who Will Grab It?
August 3, 2018
- Astellas/Daiichi Sankyo Showdown Looms as Their FLT3 Inhibitors Near Approval
July 12, 2018
- LDP Heavyweights on Guard for Push to Scrap Coverage for Patch Medications
July 5, 2018
- Kudos to MHLW for Creating New Confab, but 1st Meeting Stirs Industry Frustration
May 30, 2018
- Japan Trains Sight on CEA as Centerpiece of This Year’s Cost Containment Efforts
April 23, 2018
- With Drug Price Cuts Done, MHLW Now Running Ministry-Wide Initiative to Shave Prescriptions
April 4, 2018
- Will Drug Makers Move to Pull Plug on Off-Patent Brands under “G1” Scheme?
March 12, 2018
- With CiCLE Program Entering 2nd Year, AMED Should Release More Information on Grant Program
February 28, 2018
- Chuikyo Moving toward Conclusion on Issue of Insurance Coverage for Heparinoid Drugs
January 15, 2018
- Pricing Reform Could Goad Drug Makers to Focus Resources on PMP Hopefuls
December 28, 2017
- Unraveling MHLW/MOF Tug-of-War on Drug Pricing Reform
November 8, 2017
- With Study Group on Counterfeit Drugs to Resume Discussions this Fall, Full-Scale Discussions on Introduction of PIC/S GDP Guidelines Looming
October 10, 2017
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…